MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MLTX MoonLake Immunotherapeutics

Trading 10-12 15:29:19 EDT

10.73

-0.09

-0.83%

High10.95	Low10.72	Vol677.66K
Open10.82	D1 Closing10.82	Amplitude2.09%
Mkt Cap913.19M	Tradable Cap595.18M	Total Shares85.11M
T/O7.35M	T/O Rate1.22%	Tradable Shares55.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MLTX","market":"US","secType":"STK","nameCN":"MoonLake Immunotherapeutics","latestPrice":10.73,"timestamp":1791833357114,"preClose":10.82,"halted":0,"volume":677662,"delay":0,"changeRate":-0.008317929759704239,"floatShares":55468400,"shares":85106685,"eps":-3.813939,"marketStatus":"Trading","change":-0.09,"latestTime":"10-12 15:29:19 EDT","open":10.82,"high":10.945,"low":10.719,"amount":7352380.270905,"amplitude":0.020887,"askPrice":10.74,"askSize":475,"bidPrice":10.72,"bidSize":825,"shortable":3,"etf":0,"ttmEps":-3.813939,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"listingDate":1603166400000,"exchange":"NASDAQ","adjPreClose":10.82,"preHourTrading":{"tag":"盘前","latestPrice":10.86,"preClose":10.82,"latestTime":"09:07 EDT","volume":291,"amount":3129.663387,"timestamp":1791810453827,"change":0.04,"changeRate":0.003697,"amplitude":0.013235},"postHourTrading":{"tag":"盘后","latestPrice":10.82,"preClose":10.82,"latestTime":"19:30 EDT","volume":16619,"amount":179894.1925,"timestamp":1791588605733,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.304756,"impliedVol":0.7719,"impliedVolPercentile":0.2191},"requestUrl":"/m/hq/s/MLTX/tweets","defaultTab":"tweets","newsList":[{"id":"2673858060","title":"MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2673858060","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673858060?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:26","pubTimestamp":1791214007,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics  could receive US Food and Drug Administration approval for sonelokimab as a treatment for hidradenitis suppurativa by year-end 2027, with the completed BLA submission representing a key milestone, Wedbush Securities said in a Monday note.The company has completed its biologics license application, or BLA, for sonelokimab and has also requested a priority review designation, the brokerage said. The FDA's acceptance of the BLA should be a positive catalyst for MoonLake, regardless of review designation, according to the note.MoonLake's 52-week data from two phase 3 studies of sonelokimab showed the product candidate has \"at least comparable efficacy\" to bimekizumab, an approved treatment for the same indication, the investment firm said.The brokerage added that a decision on the filing should be released within 60 days, by the end of November, and that the review designation should be confirmed within 74 days of filing, based on the review timeline.Wedbush ha","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4139","LABU","BK4585","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673702291","title":"MoonLake Immunotherap Price Target Maintained with a $50.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2673702291","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673702291?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:09","pubTimestamp":1791202140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MLTX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672782138","title":"MoonLake Immunotherapeutics - Submits Bla to FDA for Sonelokimab to Treat Hidradenitis Suppurativa - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2672782138","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672782138?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:20","pubTimestamp":1790799650,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M14X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672984782","title":"MoonLake Submits FDA BLA for Sonelokimab in Hidradenitis Suppurativa","url":"https://stock-news.laohu8.com/highlight/detail?id=2672984782","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672984782?lang=en_us&edition=fundamental","pubTime":"2026-10-01 04:16","pubTimestamp":1790799391,"startTime":"0","endTime":"0","summary":"MoonLake submits FDA BLA for sonelokimab in hidradenitis suppurativaMoonLake Immunotherapeutics filed a BLA with the FDA on Sept. 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDLTQtWp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659215530","title":"H.C. Wainwright Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659215530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659215530?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:37","pubTimestamp":1786617468,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on MoonLake Immunotherapeutics today and set a price target of $50.00. According to T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659153348","title":"MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $50 from $45","url":"https://stock-news.laohu8.com/highlight/detail?id=2659153348","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659153348?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:13","pubTimestamp":1786615998,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nAZN4TDSHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658947711","title":"MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2658947711","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658947711?lang=en_us&edition=fundamental","pubTime":"2026-08-12 09:45","pubTimestamp":1786499150,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Hold rating on MoonLake Immunotherapeutics on August 10 and set a price target of $17.00. The compa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/moonlake-immunotherapeutics-mltx-receives-a-hold-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/moonlake-immunotherapeutics-mltx-receives-a-hold-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0708994859.HKD","MLTX","BK4207","LU0310800379.SGD","LU0029864427.USD","LU1267930573.SGD","LU0128525929.USD","GSIB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992299","title":"Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992299","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658992299?lang=en_us&edition=fundamental","pubTime":"2026-08-11 19:16","pubTimestamp":1786446984,"startTime":"0","endTime":"0","summary":"Guggenheim analyst reiterated a Buy rating on MoonLake Immunotherapeutics yesterday and set a price target of $40.00. The company’s shares closed y...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-moonlake-immunotherapeutics-mltx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658951469","title":"MoonLake Immunotherapeutics: Files for Mixed Shelf Offering, Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658951469","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658951469?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:39","pubTimestamp":1786394345,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4471PS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658742931","title":"MoonLake Immunotherapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658742931","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658742931?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:32","pubTimestamp":1786368734,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics reports results for the quarter ended June 30 - Earnings SummaryMoonLake ImmunotherapeuticsMLTX.OQreported a quarterly adjusted loss of 84 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N447161:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658931555","title":"MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals","url":"https://stock-news.laohu8.com/highlight/detail?id=2658931555","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658931555?lang=en_us&edition=fundamental","pubTime":"2026-08-10 21:08","pubTimestamp":1786367289,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics  reported Monday its Q2 loss narrowed to $0.84 per share, from a loss of $0.87 per share, a year earlier.Analysts polled by FactSet expected a loss of $0.92 per share.As of June 30, the company said it had $537.0 million in cash, cash equivalents and short-term marketable debt securities on hand, and expected it could fund operations to mid-2028.Separately, the company said its phase 3 IZAR-1 trial of sonelokimab in biologic-naive patients with psoriatic arthritis met all clinical endpoints at Week 16.The company said 42.1% of patients receiving the 60 mg dose with induction achieved an ACR50 response, while 66.5% achieved ACR20 and 41.2% achieved minimal disease activity.Among patients with skin involvement, 61% achieved PASI90 at week 16, it added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935779","title":"MoonLake's Psoriatic Arthritis Drug Meets Key Goals in Late-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935779?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:05","pubTimestamp":1786363553,"startTime":"0","endTime":"0","summary":"MoonLake's psoriatic arthritis drug meets key goals in late-stage trialAug 10 (Reuters)-MoonLake ImmunotherapeuticsMLTX.Osaid on Monday its experimental drug met all main goals in a late-stage trial i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL4N4470PP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HTGC","PBDC","PEX","BIZD","BK4135","MLTX","BK4139","FBDC","FXED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658935357","title":"MoonLake Q2 FY26 Net Loss Widens 10.3% to $61.81 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658935357","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658935357?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:50","pubTimestamp":1786362616,"startTime":"0","endTime":"0","summary":"MoonLake Q2 FY26 net loss widens 10.3% to $61.81 millionMoonLake Immunotherapeutics posted a net loss of $61.81 million, widening 10.3% year over year in the quarter ended June 30, 2026.Operating loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nNDLkSP1f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658593379","title":"MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593379","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593379?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:40","pubTimestamp":1786362014,"startTime":"0","endTime":"0","summary":"MoonLake Immunotherapeutics (MLTX) announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naive adults...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/moonlake-says-phase-3-izar-1-trial-met-all-clinical-endpoints-at-week-16-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/moonlake-says-phase-3-izar-1-trial-met-all-clinical-endpoints-at-week-16-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658593828","title":"MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593828","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593828?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:12","pubTimestamp":1786360326,"startTime":"0","endTime":"0","summary":"MoonLake (NASDAQ:MLTX) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.93) by 9.68 percent. This is a 3.45 percent increase over losses of $(0.87) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61069827/moonlake-q2-eps-0-84-beats-0-93-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938420","title":"Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938420","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938420?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:11","pubTimestamp":1786360306,"startTime":"0","endTime":"0","summary":"Switzerland's MoonLake Q2 net loss narrows as expenses fallOverviewSwitzerland biopharma reported Q2 net loss as operating expenses declined from prior quarterCompany ended Q2 with $537 mln in cash an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL1N44709J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","MLTX","VERU","BK4183","RPID","BK4121","BK4557","BK4539","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938824","title":"MoonLake Immunotherapeutics - Blinded Safety Analysis Shows no New Safety Signals for Sonelokimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938824","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938824?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:01","pubTimestamp":1786359660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470EL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658938820","title":"MoonLake Immunotherapeutics - Acr50 Primary Endpoint Met with 42.1% Response for Sonelokimab 60 Mg","url":"https://stock-news.laohu8.com/highlight/detail?id=2658938820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658938820?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:01","pubTimestamp":1786359660,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470EL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658793882","title":"MoonLake Immunotherapeutics - Phase 3 Izar-1 Trial Meets All Clinical Endpoints at Week 16 for 60 Mg Sonelokimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2658793882","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658793882?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:01","pubTimestamp":1786359660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nFWN4470EL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MLTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658980029","title":"MoonLake Immunotherapeutics Q2 EPS USD -0.84","url":"https://stock-news.laohu8.com/highlight/detail?id=2658980029","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658980029?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:00","pubTimestamp":1786359601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nPLXNMBL9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MLTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.moonlaketx.com","stockEarnings":[{"period":"1week","weight":-0.0517},{"period":"1month","weight":-0.2114},{"period":"3month","weight":-0.4686},{"period":"6month","weight":-0.3976},{"period":"1year","weight":0.1535},{"period":"ytd","weight":-0.1791}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.01118},{"month":2,"riseRate":0.5,"avgChangeRate":0.083781},{"month":3,"riseRate":0.666667,"avgChangeRate":0.033144},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.114037},{"month":5,"riseRate":0.5,"avgChangeRate":0.100872},{"month":6,"riseRate":0.833333,"avgChangeRate":0.149159},{"month":7,"riseRate":0.5,"avgChangeRate":0.052272},{"month":8,"riseRate":0.5,"avgChangeRate":0.044509},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.176073},{"month":10,"riseRate":0.5,"avgChangeRate":0.038321},{"month":11,"riseRate":0.666667,"avgChangeRate":0.098535},{"month":12,"riseRate":0.5,"avgChangeRate":0.079459}],"exchange":"NASDAQ","name":"MoonLake Immunotherapeutics","nameEN":"MoonLake Immunotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MoonLake Immunotherapeutics,MLTX,MoonLake Immunotherapeutics股票,MoonLake Immunotherapeutics股票老虎,MoonLake Immunotherapeutics股票老虎国际,MoonLake Immunotherapeutics行情,MoonLake Immunotherapeutics股票行情,MoonLake Immunotherapeutics股价,MoonLake Immunotherapeutics股市,MoonLake Immunotherapeutics股票价格,MoonLake Immunotherapeutics股票交易,MoonLake Immunotherapeutics股票购买,MoonLake Immunotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MoonLake Immunotherapeutics(MLTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MoonLake Immunotherapeutics(MLTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction